Spots Global Cancer Trial Database for refractory solid tumors
Every month we try and update this database with for refractory solid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies. | NCT00677001 | Neoplasms | R306465 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval | NCT01525394 | Refractory Soli... Lymphomas | Lenvatinib Moxifloxacin 40... Placebos (match... | 18 Years - | Eisai Inc. | |
| A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors | NCT00923728 | Refractory Soli... | AVN944 | 18 Years - | Vertex Pharmaceuticals Incorporated | |
| Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors | NCT02450149 | Refractory Soli... | sorafenib | 20 Years - | Samsung Medical Center | |
| KSH01-TCRT Solid Tumors | NCT05539833 | TCR-T Cells Refractory Soli... Relapsed Solid ... | KSH01 injection | 18 Years - 70 Years | TCRx Therapeutics Co.Ltd | |
| Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors | NCT06150365 | Refractory Soli... Relapsed Solid ... | KSX01-TCRT cell... | 18 Years - 70 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors | NCT04981691 | Refractory Mali... | anti-MESO CAR T... | 18 Years - 80 Years | Ruijin Hospital | |
| Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | NCT01956669 | Solid Tumours | Pazopanib | 1 Year - 18 Years | Novartis | |
| Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors | NCT01096030 | Neoplasms | Regorafenib (St... | 18 Years - | Bayer | |
| Study of PYX-106 in Solid Tumors | NCT05718557 | Solid Tumor | PYX-106 | 18 Years - | Pyxis Oncology, Inc | |
| Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors | NCT02691767 | Refractory Soli... | pazopanib | 19 Years - | Samsung Medical Center | |
| Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors | NCT02450136 | Refractory Soli... | pazopanib | 20 Years - | Samsung Medical Center | |
| Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer | NCT03096340 | Cancer Neoplasms Tumors Refractory Soli... Recurrent Solid... | IT-141 | 18 Years - | Intezyne Technologies, Inc. | |
| Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation | NCT04869475 | Refractory Soli... | Arsenic trioxid... | 18 Years - | Ruijin Hospital | |
| A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 | NCT02482441 | Advanced Relaps... Refractory Soli... | OMP-131R10 FOLFIRI | 18 Years - | Mereo BioPharma | |
| Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors | NCT05150457 | Refractory Soli... | BNA035 | 18 Years - | Binacea Pharma, Inc. | |
| Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | NCT01956669 | Solid Tumours | Pazopanib | 1 Year - 18 Years | Novartis | |
| Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors | NCT02691780 | Refractory Soli... | Sorafenib | 19 Years - | Samsung Medical Center | |
| Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors | NCT00394446 | Refractory Soli... | MPC-6827 | 18 Years - | Myrexis Inc. | |
| Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation | NCT04869475 | Refractory Soli... | Arsenic trioxid... | 18 Years - | Ruijin Hospital | |
| Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors | NCT02691780 | Refractory Soli... | Sorafenib | 19 Years - | Samsung Medical Center | |
| A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors | NCT00923728 | Refractory Soli... | AVN944 | 18 Years - | Vertex Pharmaceuticals Incorporated | |
| Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children | NCT02512926 | Relapsed Solid ... Refractory Soli... Relapsed Leukem... Refractory Leuk... | Carfilzomib Cyclophosphamid... Etoposide | 6 Months - 29 Years | Stanford University | |
| KSX01-TCRT Injection Project in Solid Tumors | NCT05811975 | TCR-T Cells Refractory Soli... Relapsed Solid ... | KSX01-TCRT inje... | 18 Years - 70 Years | TCRx Therapeutics Co.Ltd | |
| KSX01-TCRT Injection Project in Solid Tumors | NCT05811975 | TCR-T Cells Refractory Soli... Relapsed Solid ... | KSX01-TCRT inje... | 18 Years - 70 Years | TCRx Therapeutics Co.Ltd | |
| Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation | NCT04869475 | Refractory Soli... | Arsenic trioxid... | 18 Years - | Ruijin Hospital | |
| Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors | NCT01096030 | Neoplasms | Regorafenib (St... | 18 Years - | Bayer | |
| Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | NCT06234098 | Solid Tumor | AT-1965 Liposom... | 18 Years - | Alyssum Therapeutics | |
| Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors | NCT02450136 | Refractory Soli... | pazopanib | 20 Years - | Samsung Medical Center | |
| A Phase I/Expansion Study of Dasatinib | NCT00598091 | Refractory Soli... Pancreatic Aden... | gemcitabine dasatinib gemcitabine dasatinib | 18 Years - | Duke University | |
| A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors | NCT06006273 | Refractory Soli... | Eribulin Irinotecan Temozolomide | 1 Year - 25 Years | M.D. Anderson Cancer Center | |
| Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer | NCT03096340 | Cancer Neoplasms Tumors Refractory Soli... Recurrent Solid... | IT-141 | 18 Years - | Intezyne Technologies, Inc. | |
| A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma | NCT04718675 | Relapsed Solid ... Refractory Soli... Non-Hodgkin Lym... | KB-0742 | 12 Years - | Kronos Bio | |
| K-BASKET, TAS-117, PI3K/AKT Gene Aberration | NCT03017521 | Solid Tumor, Ad... | TAS-117 | 19 Years - | Yonsei University | |
| Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors | NCT02450149 | Refractory Soli... | sorafenib | 20 Years - | Samsung Medical Center | |
| TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) | NCT03247309 | Solid Tumor Cancer Recurrent Solid... Refractory Soli... | IMA201 Product IMADetect® | 18 Years - | Immatics US, Inc. | |
| Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia | NCT00665990 | Refractory Soli... Leukemia | Bevacizumab Sorafenib Cyclophosphamid... | - 21 Years | St. Jude Children's Research Hospital | |
| Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors | NCT03810742 | Refractory Soli... | Nanoliposomal I... | 20 Years - 70 Years | PharmaEngine | |
| Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors | NCT02691793 | Refractory Soli... | Sunitinib | 19 Years - | Samsung Medical Center | |
| An Open-Label, Dose-Escalation Study of AZD2461 | NCT01247168 | Refractory Soli... Cancer Tumor | AZD2461 | 18 Years - | AstraZeneca | |
| Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors | NCT02688881 | Refractory Soli... | sirolimus | 19 Years - | Samsung Medical Center | |
| A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 | NCT02482441 | Advanced Relaps... Refractory Soli... | OMP-131R10 FOLFIRI | 18 Years - | Mereo BioPharma | |
| MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors | NCT06030869 | Refractory Soli... Next Generation... | 18 Years - | Tianjin Medical University Second Hospital | ||
| Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia | NCT00665990 | Refractory Soli... Leukemia | Bevacizumab Sorafenib Cyclophosphamid... | - 21 Years | St. Jude Children's Research Hospital | |
| Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer | NCT03096340 | Cancer Neoplasms Tumors Refractory Soli... Recurrent Solid... | IT-141 | 18 Years - | Intezyne Technologies, Inc. | |
| A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma | NCT04718675 | Relapsed Solid ... Refractory Soli... Non-Hodgkin Lym... | KB-0742 | 12 Years - | Kronos Bio | |
| Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors | NCT02691767 | Refractory Soli... | pazopanib | 19 Years - | Samsung Medical Center | |
| Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | NCT06234098 | Solid Tumor | AT-1965 Liposom... | 18 Years - | Alyssum Therapeutics | |
| A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies. | NCT00677001 | Neoplasms | R306465 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | NCT02886897 | Hepatocellular ... Renal Cell Carc... Bladder Cancer Colorectal Canc... Non-small-cell ... Breast Cancer | D-CIK and anti-... | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors | NCT03052205 | Refractory Soli... Melanoma | IMO-2125 | 18 Years - | Idera Pharmaceuticals, Inc. | |
| Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors | NCT03810742 | Refractory Soli... | Nanoliposomal I... | 20 Years - 70 Years | PharmaEngine | |
| Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors | NCT03739827 | Malignant Solid... Other Neoplasms... Pediatric Solid... Refractory Soli... Solid Tumor | 4 Weeks - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
